Arca BioPharma

 

http://www.benzinga.com/news/14/12/5073655/...tic-af-clinical-trial-s  

In den letzten Tagen recht stark - schätze da kommt was!  

Sabby ( großer Fond und Broker) hat schon wieder zugekauft und sind jetzt mit indirekten Aktienhaltern bei über 33% - wollen die evtl. komplett übernehmen oder was steht dahinter.
Es dürft sehr sehr spannend werden in den nächsten Tagen und Wochen :-)
 

:-) man sagt ja: " Mein lieber Sabby " ;-)  

Jetzt kann keiner mehr an das Hammerprodukt ran :-)
Sehe grün für die nächste Zeit-  

gerade läuft ein Rücksetzer - hoffe die schließen 2 stellig, dann geht s relativ schnell wieder über 1 $  

 

Wow in der Nachbörse hatte die Aktie im Hoch 33% zugelegt bis ein paar Kasper mit kleinem Volumen das auf 7% schmelzen liesen.
Hat aber nichts zu sagen - vor einem großen Sprung ist die Volatilität eben höher als sonst :-)  

Wenn nur bischen mehr wie die Hälfte von dem Ziel erreicht wird sind das kurzfristig ca. 200% Chance - auf ein Jahr evtl. deutlich mehr.  

geht es jetzt los :-)  

startet durch :-))  

Heute schon über 1 $  

unter einem $ geschlossen - ich hoffe morgen geht es weiter - welche news können wir hier in nächster zeit erwarten??? du kennst dich ja anscheind gut aus mit abio - black-moon???  

http://www.arcabiopharma.com/assets/File/...presentation_Jan_2015.pdf  

http://www.nasdaq.com/press-release/...al-trial-update-20150316-01049

ARCA biopharma Provides GENETIC-AF Clinical Trial Update

By Business Wire,  March 16, 2015, 04:30:00 PM EDT  


Vote up  

loading
A A A  





GENETIC-AF Trial Evaluating Gencaro ™ as Potential Treatment for Atrial Fibrillation

Protocol Amended to Broaden Trial Population and Increase Enrollment Rate

Phase 2B of GENETIC-AF Anticipated to Complete Enrollment by Year-End 2016

WESTMINSTER, Colo.--(BUSINESS WIRE)-- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today provided an update on GENETIC-AF, the Company's Phase 2B/3 clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF).

ARCA was founded on the belief that a personalized medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA's lead development program is intended to be a direct implementation of those ideas. Gencaro is being developed as a potential treatment for AF. ARCA has identified common genetic variations that it believes may predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. AF is considered an epidemic cardiovascular disease with an estimated prevalence of at least 2.7 million Americans in 2010.

GENETIC-AF Clinical Trial

GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL (metoprolol succinate) for the treatment of AF in patients with heart failure and left ventricular systolic dysfunction (HFREF patients). The primary endpoint of GENETIC-AF is time to symptomatic AF/atrial flutter (AFL). ARCA is enrolling only HFREF patients with the genetic variant of the cardiac beta-1 adrenergic receptor, which the Company believes responds most favorably to Gencaro, the 389 arginine homozygous genotype (ADRB1 Arg389Arg). GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial seeking to enroll approximately 200 patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.

There are currently 38 active clinical trial sites in the United States and Canada. The Company anticipates that approximately 65 sites will be activated for the Phase 2B portion of GENETIC-AF. Trial enrollment, the number of patients randomized into one of the study's two treatment arms, has not met the Company's original projections, with the trial having screened 37 patients who met the general clinical inclusion criteria and signed informed consent for genotyping, resulting in 12 patients who were randomized into the trial. The percentage of screened patients who have the targeted genotype is consistent with pre-trial assumptions of approximately 50%. The Company believes the original trial eligibility criteria overly restricted the potential pool of appropriate patients for the trial and contributed to the number of screened patients who subsequently became ineligible for randomization. To address these issues, the Company, in consultation with the GENETIC-AF Steering Committee comprised of experts in the fields of electrophysiology, heart failure and clinical trial methodology, has implemented amendments to the trial protocol that the Company believes may expand the eligible target population, increase the patient screening and enrollment rate, and simplify trial procedures.

Under the revised protocol, patients in sinus rhythm who have experienced symptomatic AF in the past 120 days are now eligible for inclusion in the trial, as are patients with AF episodes lasting 7 days or less (i.e., paroxysmal AF). Previously, these patients were not eligible to be enrolled in the trial. The Company believes this expanded target population, which is substantially larger than the original target population, has the potential to improve trial screening and enrollment rates and broaden the potential commercial market for Gencaro should it achieve regulatory approval in the future. The amendments to the protocol do not fundamentally alter or impact the original endpoints of the clinical trial. Based on the projected impact of the expanded patient population and the current enrollment rate, the Company anticipates that the enrollment of 200 patients for the Phase 2B portion of the trial may be completed by the end of 2016.

The Company has met with the U.S. Food and Drug Administration to confirm the acceptability of the amendments to the protocol and received no objections.

The revised clinical trial protocol has been distributed to participating clinical trial sites for review by their respective institutional review boards (IRB), or similar committee. IRBs review and approve clinical trial protocols for trials in which their organizations participate, a process with timelines that vary significantly from IRB to IRB and is out of the Company's control. The Company does not anticipate a significant change to the current enrollment rate until the revised protocol is adopted by clinical trial sites. The Company anticipates the first trial sites to be approved, trained and operating under the revised protocol in June 2015.

"We greatly appreciate the tremendous support and feedback from the clinical investigator community participating in GENETIC-AF," said Dr. Michael R. Bristow, President and Chief Executive Officer of ARCA. "The adaptive nature of the clinical trial design for GENETIC-AF is an important feature that allows us to adapt certain aspects of the trial without compromising basic assumptions and the central goal, which is to test the hypothesis that Gencaro is safe and effective in preventing recurrent AF in a genetically defined HFREF population. We believe we have a significant opportunity to improve the treatment options for patients living with atrial fibrillation and look forward to providing future updates on the progress of GENETIC-AF."

GENETIC-AF Trial Phase 2B Projected Timeline

  -- Revised protocol distributed to participating clinical trial sites           March 2015  
-- GENETIC-AF Trial Investigators meeting and training     May 2015  
-- First trial sites operating under revised protocol     June 2015  
-- Approximately 65 clinical trial sites active in U.S. & Canada     Q4 2015  
-- Trial Enrollment Completion     YE 2016  
-- DSMB Interim Analysis Decision     1H 2017  
       

The Company's forecast of the time periods to achieve these milestones is a forward-looking statement and involves risks and uncertainties, and actual results are likely to vary as a result of a number of factors, including the factors discussed in "Risk Factors" in the Company's periodic SEC filings.

Atrial Fibrillation (AF)

Atrial fibrillation, the most common sustained cardiac arrhythmia, is considered an epidemic cardiovascular disease and a major public health burden. The estimated number of individuals with AF globally in 2010 was 33.5 million. According to the 2015 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the U.S. in 2010 ranged from 2.7 million to 6.1 million people. Hospitalization rates for AF increased by 23% among US adults from 2000 to 2010 and hospitalizations account for the majority of the economic cost burden associated with AF.

AF is a disorder in which the normally regular and coordinated contraction pattern of the heart's two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF) patients. These include toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. The Company believes there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, potential timeline for GENETIC-AF trial activities, the sufficiency of the Company's capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the SEC, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.



 

Source: ARCA biopharma, Inc.

 


This article appears in: News Headlines


Read more: http://www.nasdaq.com/press-release/...e-20150316-01049#ixzz3UdkewQAg
 

Kann mir jemand Info geben worum es geht hier oder an was die Firma arbeitet? Danke  

black-moon hat da ne Präsentation rein gestellt  

Bin dabei  

ist die präsentation nicht mehr online....kann das einer zusammenfassen?  

hier ganz aktuell - April 2015

http://www.arcabiopharma.com/wp-content/uploads/...ion-April-2015.pdf  

die hat über Nacht fast 200 % zugelegt - jetzt hier noch einen ähnlichen Sprung und ich bin sehr sehr HAPPY  :-)  

also ich habe da - gegenüber der letzten Präsentation - nichts großartig neues gefunden ?

Warum bist Du der Meinung, daß hier bald die Post abgeht (ich würds mir ja wünschen aber in der Präsentation lese ich 2017 und das gibt mir zu denken)  

da hast du Recht, viel Neues gibt es nicht und der Zeitrahmen  - ok
Aber woran ich meine Hoffnungen fest mache:
Genau wie bei Voltari hat auch hier ein Investor in den letzten Monaten seinen Anteil drastisch erhöht - das sind für mich die Vorboten, dass da was kommt.
Dazu mein Bauchgefühl, womit ich doch sehr oft richtig liege.
Auch muss der Kurs wieder über 1,-$ sonst delisting - also werden die neuen Herren schon was dafür tun, dass wir wieder über einen $ kommen.
Und sollten wir auf ca. 2-3 $ bei dieser Aktion laufen, dann wäre ich auch zufrieden.
 

ist wohl ein gutes Omen, dass du raus bist

aber wieso so schnell ??

und wo steht das mit dem Resplit, bitte ein LInk